The increase in the NADH α1 free form contribution and a corresponding decrease in the contribution of the NADH α2 protein-bound form correlate with a positive response to anti-CTLA-4 therapy expressed in the tumor growth inhibition. The gene discussed is CTLA4; the disease is neoplasm.